DermTech Inc
(Constellation Alpha Capital Corp)
In talks with DermTech Inc
DermTech is a leading genomics company in dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases and help customize drug treatment. DermTech analyzes skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech's mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs.
Rumor from
SPAC Details
SPAC Ticker : CNAC
New Ticker : DMTK
Status : Completed
Sector : Materials, Asia-focused, Healthcare
Target :
not announced
Trust account : $ 200.0 million
Underwriters : Cowen, I-Bankers
Lawyers :
IPO : Jun. 20, 2017
Target Announced : May. 29, 2019
Merger Closed : Aug. 29, 2019
Liquidation : Jun. 19, 2019
Pres, CEO & Director : Dr. John D. Dobak M.D.
CFO, Treasurer & Sec. : Kevin Sun M.B.A.
Chief Operating Officer : Claudia Ibarra
Gen. Counsel : Ray Akhavan J.D.
Chief Commercial Officer : Todd Michael Wood
Chief Scientific Officer : Michael Howell Ph.D.
Sr. Director of Investor Relations : Steve E. Kunszabo
Chief Compliance Officer : Jennifer Eilemberg
VP of Sales : Ray Bassi
Chief Medical Affairs Officer : Dr. Burkhard Jansen M.D.
Performance
Common Price : $ 2.78
NAV : $ 10.00
Premium to NAV : -72%
Warrant Price : $
Warrant Strike : $ 11.50
Warrant Intrinsic Value : $ 0.00
Total Return : -86%
Annualized Return : -31%
Annualized Volatility : 82%
Sharpe Ratio : -0.57
Maximum Drawdown : 98%
DermTech Inc
DermTech is a leading genomics company in dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases and help customize drug treatment. DermTech analyzes skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech's mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs.
Target announced on May. 29, 2019
Merger closed on Aug. 29, 2019
Valuation
Shares outstanding : 30.2 million
Current Equity Value at $ per share :
$ 54.1 million
Pro forma Equity Value at Target Announcement : $ 0
Pro forma Enterprise Value at Target Announcement : $ 0
No graph available.
Source: Investor presentation. For the latest financial projections please refer to the investor relations department of the company.